SCHEMBL1438344

SCHEMBL1438344

CON(C)C(=O)c1ccc(F)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.48
MAPT P10636 3/20 0.47
MEN1 O00255 1/20 0.47
CASP3 P42574 1/20 0.47
KMT2A Q03164 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
TAS1R3 Q7RTX0 2/20 0.45
TAS1R1 Q7RTX1 2/20 0.45
TAS1R2 Q8TE23 2/20 0.45
GPBAR1 Q8TDU6 1/20 0.44
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
HTT P42858 1/20 0.41
SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31073591 1.00 MLYCD (0.48) MLYCDMAPTMEN1CASP3KMT2A
SCHEMBL2655175 0.85 SLC6A3 (0.54) MLYCDMAPTMEN1KMT2AKDM4E
SCHEMBL2883042 0.85 CES2 (0.52) MLYCDMEN1KMT2AMAOAMAOB
SCHEMBL1782199 0.83 GPBAR1 (0.48) MAPTMEN1CASP3KMT2ASENP7
SCHEMBL29902993 0.83 GPBAR1 (0.48) MAPTMEN1CASP3KMT2ASENP7
SCHEMBL8988251 0.82 MLYCD (0.45) MLYCDMAPTMEN1KMT2AALDH1A1
SCHEMBL760870 0.82 MLYCD (0.49) MLYCDKDM4EHSP90AA1HSP90AB1
SCHEMBL4568350 0.82 MLYCD (0.49) MLYCDMEN1KMT2AGPBAR1KDM4E
SCHEMBL22065246 0.81 MLYCD (0.44) MLYCDMEN1KMT2AALDH1A1KDM4E
SCHEMBL14720018 0.81 MLYCD (0.48) MLYCDMEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470502-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS Novartis AG (CH) 2012-07-04 EP disclosed
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed
WO-2011023677-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 MLYCD 1620/4885MAPT 582/4885MEN1 510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.